**Core Concept**
Irinotecan is a topoisomerase I inhibitor used in the treatment of colorectal cancer. It works by stabilizing the topoisomerase I-DNA complex, thereby preventing DNA replication and leading to cell death.

**Why the Correct Answer is Right**
Irinotecan is metabolized by carboxylesterase to its active metabolite, SN-38. SN-38 is a potent inhibitor of topoisomerase I, which is involved in DNA replication. The inhibition of topoisomerase I leads to DNA damage and ultimately cell death. Irinotecan is also a substrate for the efflux transporter P-glycoprotein, which can affect its pharmacokinetics.

**Why Each Wrong Option is Incorrect**
**Option A:** Irinotecan is actually a topoisomerase I inhibitor, not a topoisomerase II inhibitor. Topoisomerase II is a different enzyme involved in DNA replication.
**Option B:** Irinotecan is metabolized by carboxylesterase to SN-38, which is its active metabolite. This is not true for the other options.
**Option C:** Irinotecan is not a platinum-based chemotherapeutic agent. It belongs to a different class of drugs known as topoisomerase inhibitors.

**Clinical Pearl / High-Yield Fact**
Irinotecan is a prodrug that requires metabolic activation by carboxylesterase to produce its active metabolite, SN-38. This is an important consideration when managing patients on this medication.

**Correct Answer: A. Irinotecan is a topoisomerase I inhibitor, not a topoisomerase II inhibitor.**